Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.04 – $1.20
Volume92,933
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.25M
Price / earnings
—
Price / book
0.32×
Price / sales
—
EV / sales
—
EV / EBITDA
0.45×
Profitability
Earnings per share
-$5.76
Return on assets
-143.76%
Return on equity
-169.73%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.52×
Quick ratio
6.52×
Cash ratio
6.13×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AMIX, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.59M
$1.26M
$1.28M
$1.62M
$5.17M
$1.83M
$1.7M
$1.7M
Research and development
$1.58M
$1.52M
$1.46M
$1.72M
$2.37M
$1.59M
$1.55M
$1.04M
Total operating expenses
$3.18M
$2.77M
$2.74M
$3.34M
$7.53M
$3.42M
$3.25M
$2.75M
Operating income
-$3.18M
-$2.77M
-$2.74M
-$3.34M
-$7.53M
-$3.42M
-$3.25M
-$2.75M
Interest expense
$0
$0
$0
$0
$0
$0
-$46K
-$45K
Income before taxes
-$3.13M
-$2.73M
-$2.67M
-$3.26M
-$7.45M
-$3.34M
-$3.19M
-$2.71M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.13M
-$2.73M
-$2.67M
-$3.26M
-$7.45M
-$3.34M
-$3.19M
-$2.71M
Net income attributable to common shareholders
-$3.13M
-$2.73M
-$2.67M
-$3.26M
-$7.45M
-$3.34M
-$3.19M
-$2.71M
EBITDA
-$3.17M
-$2.77M
-$2.73M
-$3.34M
-$7.53M
-$3.42M
-$3.2M
-$2.7M
Basic earnings per share
-$2.51
-$5.02
-$4.90
-$7.56
-$29.02
-$22.69
-$24.33
-$30.66
Diluted earnings per share
-$2.51
-$5.02
-$4.90
-$7.56
-$29.02
-$22.69
-$24.33
-$30.66
Recent news
Company coverage with links to the original publishers.
Autonomix Medical announced a warrant inducement agreement with an investor to exercise outstanding July 2026 Warrants for 857,462 shares at $5.75 per share, generating approximately $4.9 million in gross proceeds. In exchange, the company issued new Series E-1 and E-2 warrants to purchase 535,913 shares each at $6.25 per share. The transaction is expected to close on August 26, 2026.
Autonomix Medical announced positive preclinical study results showing its neural sensing platform can detect, localize, and confirm changes in renal neural activity. The technology enables physiological feedback during renal denervation procedures, potentially addressing current limitations where physicians rely on anatomical landmarks rather than direct neural information. The company plans further preclinical and clinical studies to evaluate physiology-guided renal denervation applications.
Autonomix Medical announced a warrant inducement agreement where an investor will exercise outstanding warrants to purchase 428,731 shares at $6.00 per share, generating approximately $2.6 million in gross proceeds. In return, the company will issue new Series D-1 and D-2 warrants with a $5.75 exercise price. The transaction is expected to close on or about July 15, 2026.
Autonomix Medical will present two podium sessions at the Transcatheter Cardiovascular Therapeutics Annual Scientific Conference, highlighting their first-in-human clinical study on transvascular energy delivery for pancreatic cancer pain mitigation.
Autonomix Medical, a medical device company developing innovative nerve-targeted treatment technologies, will present at the Webull Financial Corporate Connect Webinar Series on August 21, 2025, discussing their microchip-based intravascular nerve sensing platform.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.